---
title: "Cardiol opens a US$75 million Jefferies share sale with its stock near US$1"
url: "https://aibio.space/news/cardiol-opens-75-million-jefferies-share-sale-stock-near-1/"
event_date: "2026-11-03"
date_published: "2026-11-05"
description: "No shares have been sold yet. At the November 2 close of US$1.04, selling the full amount would mean issuing more than half as many new shares as are outstanding now."
---

# Cardiol opens a US$75 million Jefferies share sale with its stock near US$1

Cardiol Therapeutics signed an open market sale agreement with Jefferies LLC on November 3 that lets it sell up to US$75 million of common shares on Nasdaq over time, with Jefferies taking a commission of up to 3.0% of gross proceeds. Chief Financial Officer Christopher Waddick signed for the company, which is run by President and Chief Executive Officer David Elsley. The agreement raises no money by itself: no shares have been sold, and Cardiol says it is under no obligation to sell any. Its size is the problem. The stock closed at US$1.04 on Nasdaq on November 2, and selling the full amount near that price would mean issuing more than half as many new shares as the 122,579,738 already outstanding. In Cardiol's favor, the company said in September that existing capital should carry its Phase III MAVERIC trial to completion, so it does not need this money to reach that result. [Sales agreement](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122174/tm2628681d1_ex99-1.htm) · [Prospectus supplement](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122171/tm2628684d1_suppl.htm) · [November 3 release](https://www.sec.gov/Archives/edgar/data/1702123/000127956926001022/ex991.htm) · [Form 6-K](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122174/tm2628681d1_6k.htm)

Shares can be sold only on Nasdaq or other US markets, not in Canada. The program runs under a prospectus supplement dated November 3, 2026, to base shelf prospectuses dated September 15, 2026, and a Form F-10 registration statement that became effective on September 16, 2026. That shelf covers up to US$150 million of securities, so this program uses half of it. Each placement notice sets a floor price, which cannot be lower than US$1.00 unless Jefferies consents, and the November 2 close sat just above that level. Either side can end the agreement on ten days' notice. [Sales agreement](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122174/tm2628681d1_ex99-1.htm) · [Prospectus supplement](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122171/tm2628684d1_suppl.htm) · [September 10 release](https://www.sec.gov/Archives/edgar/data/1702123/000127956926000875/ex991.htm)

## Who is on the deal

Jefferies LLC is the sales agent. Borden Ladner Gervais LLP is Canadian counsel to Cardiol and Troutman Pepper Locke LLP is its US counsel, while DLA Piper LLP (US) advises Jefferies on US law. The prospectus supplement names no Canadian counsel for Jefferies. Cardiol will reimburse up to US$100,000 of Jefferies' legal fees tied to signing and puts its other offering expenses at about US$450,000. The Toronto Stock Exchange has conditionally approved the program. [Prospectus supplement](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122171/tm2628684d1_suppl.htm) · [Sales agreement](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122174/tm2628681d1_ex99-1.htm) · [November 3 release](https://www.sec.gov/Archives/edgar/data/1702123/000127956926001022/ex991.htm)

## How much cash Cardiol has and what it burns

Cardiol reports in Canadian dollars. It held C$26,081,066 in cash and cash equivalents on June 30, up from C$21,416,684 at the end of 2025 after a January unit financing. Operating activities used C$11,896,810 in the first half, and the six-month net loss was C$16,900,416. The company has no operating revenue, though management found no material going concern uncertainty. Its runway guidance has moved around. In August, Cardiol said its June working capital would fund operations into Q4 2027. On September 16 it said warrant exercises had brought in over US$7 million and stretched the runway into H1 2028. A week later it put the runway into Q1 2028. The use of proceeds table also excludes an estimated US$2,500,000 to US$3,000,000 per quarter of cash general and administrative costs. [Q2 MD&A](https://www.sec.gov/Archives/edgar/data/1702123/000110465926094885/tm2622666d1_ex99-2.htm) · [September 16 release](https://www.sec.gov/Archives/edgar/data/1702123/000127956926000889/ex991.htm) · [September 23 release](https://www.sec.gov/Archives/edgar/data/1702123/000127956926000905/ex991.htm) · [Prospectus supplement](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122171/tm2628684d1_suppl.htm)

Shareholders have been diluted repeatedly. Cardiol sold units at US$1.00 in October 2025, issuing 9,955,000 shares on October 17 and 1,470,000 on October 20, then 11,423,078 shares in units at C$1.30 in January 2026. Shares outstanding rose from 116,822,671 at August 11 to 122,579,738 at November 2. The Nasdaq close was US$1.99 on September 14, so the price had roughly halved before the program was announced. [Prospectus supplement](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122171/tm2628684d1_suppl.htm) · [Q2 financial statements](https://www.sec.gov/Archives/edgar/data/1702123/000110465926094885/tm2622666d1_ex99-1.htm) · [Q2 MD&A](https://www.sec.gov/Archives/edgar/data/1702123/000110465926094885/tm2622666d1_ex99-2.htm)

## What the money would pay for

The supplement puts costs on three items: US$5,000,000 to complete a New Drug Application for CardiolRx, timing to be determined and dependent on MAVERIC; US$3,000,000 to complete a Phase 1 study of CRD-38 in H2 2027; and US$10,000,000 to start a Phase II study of CRD-38, timing also undetermined. Together that is less than a quarter of the US$75 million. Management keeps broad discretion over the rest, which goes to general corporate purposes. [Prospectus supplement](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122171/tm2628684d1_suppl.htm)

MAVERIC is a randomized, double-blind, placebo-controlled trial of CardiolRx in recurrent pericarditis. It had enrolled 110 patients by September 23. After a blinded review found fewer recurrences than expected, the steering committee recommended expanding it to up to 150 patients. Elsley called the lower rate "an observation we view as encouraging". A blinded review cannot show which arm the events fell in, and the company says the extra patients are needed to keep the trial's planned statistical power. Topline results slipped from Q1 2027 to mid-2027, leaving less than a year between the expected readout and the end of the stated runway. Cardiol describes its completed Phase II ARCHER study in acute myocarditis as positive. CRD-38, a subcutaneous formulation aimed at heart failure, has not yet been tested in people. Cardiol says it will disclose the number and average price of any shares sold in its financial statements or MD&A. [September 23 release](https://www.sec.gov/Archives/edgar/data/1702123/000127956926000905/ex991.htm) · [September 10 release](https://www.sec.gov/Archives/edgar/data/1702123/000127956926000875/ex991.htm) · [Prospectus supplement](https://www.sec.gov/Archives/edgar/data/1702123/000110465926122171/tm2628684d1_suppl.htm)

Sources

- https://www.sec.gov/Archives/edgar/data/1702123/000110465926122174/tm2628681d1_ex99-1.htm
- https://www.sec.gov/Archives/edgar/data/1702123/000127956926001022/ex991.htm
- https://www.sec.gov/Archives/edgar/data/1702123/000110465926122174/tm2628681d1_6k.htm
- https://www.sec.gov/Archives/edgar/data/1702123/000110465926122171/tm2628684d1_suppl.htm
- https://www.sec.gov/Archives/edgar/data/1702123/000110465926094885/tm2622666d1_ex99-2.htm
- https://www.sec.gov/Archives/edgar/data/1702123/000110465926094885/tm2622666d1_ex99-1.htm
- https://www.sec.gov/Archives/edgar/data/1702123/000127956926000875/ex991.htm
- https://www.sec.gov/Archives/edgar/data/1702123/000127956926000889/ex991.htm
- https://www.sec.gov/Archives/edgar/data/1702123/000127956926000905/ex991.htm
